1.Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349: 1498–1504.
2.Murray C, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996; 274(5288): 740–743.
3.Greenberg PE, Kessler RC, Birnbaum HG, etal. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64: 1465–1475.
4.Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001; 62: 10–17.
5.Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003; 53: 743–753.
6.Janicak PG, Marder S, Pavuluri M. Principles and Practice of Psychopharmacotherapy, 5th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 256–263.
7.Fava M, Rush AJ, Trivedi M, etal. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26: 457–494.
8.Rush AJ, Fava M, Wisniewski SR, etal. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004; 25: 119–142.
9.Trivedi MH, Rush AJ, Wisniewski SR, etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am J Psychiatry. 2006; 163: 28–40.
10.Rush AJ, Trivedi MH, Wisniewski SR, etal. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354: 1231–1242.
11.Fava M, Rush AJ, Wisniewski SR, etal. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry. 2006; 163: 1161–1172.
12.McGrath PJ, Stewart JW, Fava M, etal. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1531–1541.
13.Nierenberg AA, Fava M, Trivedi MH, etal. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1519–1530.
14.Rush AJ, Trivedi MH, Wisniewski SR, etal. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163: 1905–1917.
15.Janicak P, O'Reardon JP, Sampson SM, etal. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008; 69: 222–232.
16.Janicak PG, Nahas Z, Lisanby SH, etal. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010; 3: 187–199.
17.George MS, Lisanby SH, Avery D, etal. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010; 67: 507–516.
18.Avery DH, Isenberg KE, Sampson SM, etal. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clincical response in an open-label extension trial. J Clin Psychiatry. 2008; 69: 441–451.
19.O'Reardon JP, Solvason HB, Janicak PG, etal. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62: 1208–1216.
20.Demitrack MA, Thase M. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009; 42: 5–38.
21.Carpenter LL, Janicak PG, Aaronson ST, etal. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012; 29(7): 587–596.
22.Connolly KR, Helmer A, Cristancho MA, etal. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012; 73(4): e567–e573.
23.Shafi MM, Westover MB, Fox MD, etal. Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging. Eur J Neurosci. 2012; 35(6): 805–825.
24.Pascual-Leone A, Tormos JM, Keenan J, etal. Study and modulation of human cortical excitability with transcranial magnetic stimulation. J Clin Neurophysiol. 1998; 15: 333–343.
25.Wells KB, Stewart A, Hays RD, etal. The functioning and well-being of depressed patients—results from the medical outcomes study. JAMA. 1989; 262: 914–919.
26.Broadhead WE, Blazer DG, George LK, etal. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990; 264: 2524–2528.
27.Kennedy N, Foy K, Sherazi R, etal. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007; 9: 25–37.
28.Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2002.
29.Fayers PM. Quality of Life: Assessment, Analysis and Interpretation. West Sussex, UK: Wiley; 2002.
30.Judd LL, Akiskal HS, Zeller PJ, etal. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000; 57: 375–380.
31.Trivedi MH, Rush AJ, Wisniewski SR, etal. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67(2): 185–195.
32.Wisniewski SR, Rush AJ, Bryan C, etal. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007; 195(3): 219–225.
33.McCall WV, Rosenquist PB, Kimball J, etal. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT. 2011; 27: 97–102.
34.Solomon DA, Leon AC, Coryell W, etal. Predicting recovery from episodes of major depression. J Affect Disord. 2008; 107: 285–291.
35.Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473–483.
36.Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 53–72.
37.Mann R, Gilbody S, Richards D. Putting the “Q” in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009; 44(7): 569–578.
38.Ware JE Jr, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: QualityMetric Incorporated, 1993, 2000.
41.Macran S, Kind P. “Death” and the valuation of health-related quality of life. Medical Care. 2001; 39(3): 217–227.
42.Katzelnick DJ, Duffy FF, Chung H, etal. Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv. 2011; 62(8): 929–935.
43.Cui Z, Faries DE, Gelwicks S, Novick D, Liu X. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ. 2012; 15: 134–144.
44.Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010; 122: 184–191.
45.Ware JE Jr, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1, 2nd ed.Lincoln, RI: QualityMetric Incorporated; 2001.
46.Dunner DL, Rush AJ, Russell JM, etal. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67: 688–695.
47.Gunther OH, Roick C, Angermeyer MC, etal. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2007; 105: 81–91.
48.Sobocki P, Ekman M, Agren H, etal. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007; 10: 153–160.
49.Simon GE, Revicki DA, Grothaus L, etal. SF-36 summary scores: are physical and mental health truly distinct? Med Care. 1998; 36: 567–572.
50.Garcia-Cebrian A, Bauer M, Montejo AL, etal. Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry. 2008; 23: 57–65.
51.Walker V, Streiner DL, Novosel S, etal. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol. 1995; 15: 60S–67S.
52.Reed C, Monz BU, Perahia DG, etal. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009; 113: 296–302.
53.Kroenke K, West SL, Swindle R, etal. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. JAMA. 2001; 286: 2947–2955.
54.Yatham LN, Lecrubier Y, Fieve RR, etal. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004; 6(5): 379–385.
55.ten Doesschate MC, Koeter MWJ, Bockting CLH, etal. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1–3): 126–132.
56.Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004; 2: 20.
57.Peveler R, Kendrick T, Buxton M, etal. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005; 9(16): 1–134.